
Caregiver Burden is Low Nine to Twelve Months after Ventricular Assist Device Implantation
Author(s) -
Roxana Ghashghaei,
Hao Tran,
Jorge Silva,
Barry Greenberg,
Denise Barnard,
Eric Adler
Publication year - 2016
Publication title -
the vad journal
Language(s) - English
Resource type - Journals
ISSN - 2378-2706
DOI - 10.14434/vad.v2i0.27946
Subject(s) - caregiver burden , spouse , medicine , heart failure , ventricular assist device , physical therapy , gerontology , disease , dementia , sociology , anthropology
Background
Prior studies have found that caregivers of chronically ill patients, including those with heart failure, have significant stress and burden. Ventricular Assist Devices (VADs) are a promising therapeutic modality for end stage heart failure. However, caregiver burden has not previously been studied in the caregivers of VAD patients.
Methods
We studied 31 caregivers of VAD patients receiving care at University of California, San Diego. Validated instruments tools, such as the Bakas Caregiving Outcomes scale and Oberst Caregiving Demand and Difficulty sub-scales, were used to measure the caregivers’ psychological burden.
Results
Nearly half of the caregivers were the patient’s spouse or partner (55%) with a mean age of 57 years. When evaluating caregiver burden difficulty, 23/31 (74.2%) of the caregivers experienced little to no difficulty, 5/31 (16.1%) had mild difficulty, and 3/31 (9.6%) noted moderate difficulty. When assessing caregiver burden demand, 17/31 (54.8%) experienced little to no demand, 8/31 (25.8%) reported mild to moderate, 5/31 (16.1%) noted moderate to severe, and 1/31 (3.2%) had severe demand. Using the Baka’s scale, 27/31 (87.1%) reported that VADs were not disruptive to their lives.
Conclusions
In this single center study, we found that 80-90% of VAD caregivers had little caregiver burden difficulty or demand, which is significantly less than published studies of caregivers of patients with other chronic diseases. Further study will be required to validate these findings and compare them to other therapies for end stage heart failure, such as cardiac transplantation.